Thrombolysis in Acute Childhood Stroke: Design and Challenges of the Thrombolysis in Pediatric Stroke Clinical Trial

Catherine Amlie-Lefond a Anthony K.C. Chan d Adam Kirton e
Gabrielle deVeber f Collin A. Hovinga b Rebecca Ichord c Derek Stephens f
Osama O. Zaidat a The Thrombolysis in Pediatric Stroke (TIPS) Investigators

a Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisc., b Departments of Clinical Pharmacy and Pediatrics, University of Tennessee Health Science Center, Memphis, Tenn., and c Department of Neurology and Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pa., USA; d Department of Pediatrics, McMaster University, Hamilton, Ont., e Department of Pediatrics and Clinical Neuroscience, University of Calgary, Calgary, Alta., and f Department of Neurology, Hospital for Sick Children, Toronto, Ont., Canada

Key Words
Acute childhood stroke · Thrombolysis · Tissue plasminogen activator

Abstract
Background: Although tissue plasminogen activator (tPA) has revolutionized the treatment of acute ischemic stroke in adults, no thrombolysis trials in childhood stroke have been conducted. Experience in adults cannot be applied to children due to fundamental age-related differences in coagulation systems, stroke pathophysiology and neuropharmacology. Obstacles to acute treatment trials in childhood stroke include delays in diagnosis and minimizing risk in a vulnerable population. Study Design: Thrombolysis in Pediatric Stroke (TIPS) is an international multicenter study to assess the safety of intravenous tPA within 0–3 h and intra-arterial tPA within 3–6 h of onset of arterial ischemic stroke in childhood. Through the International Pediatric Stroke Study, 30 international centers will enroll a total of 48 patients: 24 will be treated with intravenous tPA (0.6, 0.75, 0.9, and 1.0 mg/kg) using the classical dose-finding method, and 24 will be treated with intra-arterial tPA (maximum 0.2, 0.3, 0.4, and 0.5 mg/kg) using a Bayesian dose-finding method. Conclusion: The TIPS trial will be the first clinical trial exploring the safety and feasibility of systemic and local thrombolytic therapy in childhood stroke and the obstacles in conducting such a trial.

Introduction
Although tissue plasminogen activator (tPA) has revolutionized the treatment of acute arterial ischemic stroke (AIS) in adults [1], no acute interventional trials have been completed in childhood AIS.

Children often reach tertiary medical care within the 0- to 6-hour time window required for tPA [2, 3], however, age-appropriate tPA safety data and dosing guidelines are lacking. In the absence of pediatric guidelines, tPA is regularly given to children outside of the recommended guidelines for use of tPA in adults [4]. This variability in practice reflects the dearth of research on which to base interventions and is associated with a high frequency of adverse outcomes.

The results of research in adults cannot be applied to children due to fundamental age-related differences in
the neurological, cerebrovascular, and coagulation systems, as well as in stroke pathophysiology and developmental pharmacological differences. The concept of developmental hemostasis is now universally accepted [5, 6] and suggests that the optimal dose of tPA in adults may not apply to children. Consequently, clinical trials to assess the safety and feasibility of acute treatment for childhood stroke are of the utmost urgency.

The purpose of the Thrombolysis in Pediatric Stroke (TIPS) study is to establish the safety and feasibility of intravenous and intra-arterial tPA for acute AIS in childhood.

Aims of the Study

The TIPS trial will test the hypothesis that tPA can be given safely in acute childhood AIS. There are two primary aims of the study: to determine the maximal safe dose of intravenous tPA for children within 0–3 h from onset of acute AIS, and to determine the most desirable safe dose of intra-arterial tPA for children within 3–6 h from onset of acute AIS. As a secondary aim of the study, neurologic and functional outcome measures will be performed at 3 months following stroke.

Research Design and Methods

Overview of the Study Design

TIPS is a 5-year, prospective cohort, open-label dose finding trial of the safety and feasibility of intravenous and intra-arterial tPA to treat acute childhood AIS. Thirty international pediatric tertiary care institutions identified through the International Pediatric Stroke Study (IPSS) will participate as clinical sites for this study. The IPSS (http://app3.ccb.sickkids.on.ca/cstrokestudy) is a consortium of child neurologists, hematologists, and pharmacologists dedicated to the prevention and treatment of stroke in childhood [7]. This multinational research collaboration allows for pooling of patients and resources and ensures a larger and more ethnically diverse cohort [8].

Inclusion and Exclusion Criteria

The inclusion and exclusion criteria from the NINDS tPA trial for intravenous tPA in adults with acute stroke [9] were modified for the TIPS trial. Criteria for time from stroke onset is 0–3 h for initiation of treatment by intravenous tPA, and 3–6 h for initiation of treatment for intra-arterial tPA. A clinically significant neurological deficit as defined by a score of $\geq 10$ and $\leq 30$ on the pediatric version of the National Institute of Health Stroke Scale (PedNIHSS) [10] that is not improving is required prior to initiation of tPA administration. A minimum PedNIHSS score $\geq 10$ was chosen to ensure that only patients with a significant deficit were exposed to the risk of tPA, which is similar to other tPA trials [9, 11]. Preliminary data suggest that a PedNIHSS score of 10 predicts poor outcome in childhood stroke [12].

Modifications of the NINDS tPA trial inclusion and exclusion criteria were used to optimize safety and maximize patient homogeneity in TIPS.

Age. Children aged 2–17 years are eligible for the study. Children below 2 years of age are excluded for several reasons: (1) stroke is more difficult to identify in children less than 2 years of age due to their preverbal status; (2) developmental hemostasis suggests that very young children may have different responses to thrombolytic agents than older children, and (3) vessel size in young infants may make cerebral angiography more difficult. As children achieve 80% of their adult head circumference by 2 years of age, eligible children will have readily accessible cerebral vasculature.

Seizure at Stroke Onset. While stroke in adults rarely presents with acute seizures, 50% of children have seizures within 24 h of stroke onset. Unlike adults [13], the presence of seizures is not predictive of hemorrhagic stroke [14], therefore, the TIPS trial does not exclude patients with seizure at stroke onset. However, patients in whom an accurate pretreatment PedNIHSS score cannot be obtained due to ongoing seizures, postictal state, or alteration in consciousness due to seizure treatment will be excluded.

Pregnancy. As plasminogen activators and inhibitors are altered by pregnancy [15] and the risk of tPA to the fetus is undefined, pregnant patients are excluded.

Sickle Cell Disease. Patients with sickle cell disease are excluded. Although American Heart Association guidelines do not exclude adults with sickle cell disease [16], children with acute stroke in sickle cell disease are usually treated with transfusion. In addition, the risk of intracranial hemorrhage may be increased in sickle cell disease due to occult cerebral vasculopathy [17].

Neuroimaging to Confirm Infarction and Arterial Occlusion. In adults, the sudden onset of a focal neurological deficit can usually be reliably ascribed to acute stroke, and the NINDS study only required head CT scan without hemorrhage for neuroimaging entry criteria. In contrast, approximately one fifth of children presenting with an acute neurological deficit have a ‘stroke mimic’ such as migraine, seizure, tumor, infection or psychogenic diagnosis, rather than stroke [18]. Definitive radiological confirmation of acute AIS is therefore required for enrollment in the TIPS study and must satisfy two principle criteria: (1) acute, focal cerebral infarction with restricted diffusion in a known arterial territory consistent with the clinical syndrome, and (2) evidence of arterial occlusion in the same territory on cerebrovascular imaging. Satisfaction of these criteria will usually require MRI and MRA studies. Alternatively, a head CT scan that is either normal or shows mild, early hypodensity in an arterial territory consistent with the clinical syndrome combined with a CT angiogram demonstrating the required arterial occlusion could substitute. Prior to administration of intra-arterial tPA, persistent occlusion will be documented on conventional cerebral angiography.

Challenges Addressed in the TIPS Study Design

Although tPA has been used anecdotally in children with stroke [19–30], no standards regarding dosing, indications/contraindications, or outcome are available. A substantial publication bias also limits the interpretation
of these reports [31]. The TIPS study was designed to address significant obstacles to an interventional trial in acute childhood stroke.

**Feasibility of Adequate Patient Recruitment**

Two thirds of children with acute stroke present for care within the 3- to 6-hour window typically required for thrombolytic treatment. These short prehospital times are an advantage for emergent intervention options in children with stroke. However, significant delay in diagnosis of stroke often occurs after presentation for care [32, 33].

Despite delays in diagnosis, recent studies have found that approximately 5–19% of children presenting acutely with stroke are eligible for intravenous or intra-arterial tPA depending on interpretation of relative contraindications [32–34]. Using a minimal estimate of 5–6% eligibility rate for this trial, 960 children will need to be screened at 30 institutions over 4 years, which is an average of 8 acute AIS cases screened per year per center. A review of patients submitted to the IPSS database from centers planning to enroll in TIPS and site investigator interviews suggest that the TIPS sites will screen on average 12–16 patients per site per year.

As physician awareness of stroke in childhood increases, and in particular as protocols for neuroimaging and treatment of stroke are instituted, the in-hospital delay is expected to decrease, thus the percentage of children presenting with acute ischemic stroke who are eligible for tPA will likely increase with time. Children with first-time acute AIS only rarely meet exclusion criteria in adults, so a significant proportion diagnosed within the time window should qualify for thrombolysis.

**Frequency of Posterior Circulation Stroke in Childhood**

Studies on interventional management of stroke in adults sometimes limit enrollment to patients with anterior circulation strokes [35, 36], allowing for a more homogenous population. In approximately one third of cases of childhood acute stroke reported to the IPSS the posterior circulation is involved [37]. The TIPS study includes
posterior circulation stroke despite the potential disadvantage of a less homogenous population, as limiting the patient enrollment to anterior circulation stroke would exclude a significant proportion of children with AIS with the potential risk of adverse outcome, thereby limiting applicability of the results of the TIPS trial.

Developmental Hemostasis

The developmental nature of the hemostatic system including the fibrinolytic system is now universally accepted [5, 6, 38]. Plasminogen concentrations are approximately 50% of adult values at birth, but reach adult values by 1 year of age. The blood concentration and stimulated release of endogenous tPA also show maturational differences. From 1 to 16 years of age, baseline tPA concentrations in blood are about 50% lower than in adults. Plasminogen activator inhibitor-1 (PAI-1) binds with tPA and thereby inhibits tPA's activity and influences tPA's hepatic clearance. PAI-1 concentrations overall are increased in children compared to adults. In contrast, plasminogen and its inactivating protein, α₂-antiplasmin, do not change significantly between 1 year and adulthood. The lower baseline levels of tPA and increased PAI concentrations, which suggest a less active innate fibrinolytic system in children, indicate that an increased tPA dose relative to adults to promote fibrinolysis may be necessary. Furthermore, the ratio of tPA to PAI-1 is reversed throughout childhood compared to adults. Thus safe dosing of fibrinolytic therapy in children cannot be extrapolated from adult data.

Conventional Angiography and Intra-Arterial Lysis in Childhood

Conventional angiography in childhood is safe [39] and has been used successfully for intra-arterial thrombolysis in childhood stroke [19, 22, 23, 25, 40]. To maximize safety in TIPS, microcatheter intracranial superselective hand injection angiography just proximal to the clot or within the clot is discouraged due to potentially increased risk of intracranial hemorrhage [41]. Adjunctive soft tip microwire may be passed through the clot, but no other mechanical interventions will be performed.

Location of angiographic occlusion, distal perfusion, and collateral flow will be graded according to the TICI grading scale [42]. Administration of a given dose will occur until recanalization of a TICI 2c or better is achieved, at which point administration will be stopped. Other indications for termination of administration include evidence of contrast extravasation, unexplained clinical deterioration of the patient, infusion of the maximal dose of tPA, or at the discretion of the treating interventionalist. Radiation exposure will be limited by using the shortest possible fluoroscopy time including use of pulse rather than continuous fluoroscopy with appropriate patient shielding and optimal coning.

In Prolyse in Acute Cerebral Thromboembolism, a study of intra-arterial pro-urokinase in middle cerebral artery stroke, concomitant heparin was reduced from 100 IU/kg bolus followed by 1,000 IU/h infusion for 4 h to 2,000 IU bolus and 500 IU/h due to an increased rate of symptomatic intracranial hemorrhage in the high-dose heparin group [35]. In TIPS, an intravenous heparin bolus of 30 units/kg (maximum 2,100 units) at identification of the clot will be administered followed by intravenous continuous heparin infusion at 6 units/kg/h (maximum 420 units/h) until completion of the procedure. This dose was based on an informal survey of neuro-interventionalists with experience in children and hematologists, and extrapolation from the Interventional Management of Stroke (IMS) and the Prolyse in Acute Cerebral Thromboembolism trial methodology.

Administration of Intravenous and Intra-Arterial tPA

Dose Determination and Dose Finding Method for the Intravenous Arm

The classical safety dose finding method [43] will be used to choose a safe dose among 4 doses of intravenous tPA: 0.6, 0.75, 0.9, and 1.0 mg/kg. The initial dose in the intravenous arm will be 0.6 mg/kg, and escalations are planned in groups of 3 patients. Toxicity for dose escalation is symptomatic intracranial hemorrhage within 48 h of tPA. Symptomatic intracranial hemorrhage will be defined as a parenchymal hemorrhage involving >30% of the infarcted area (PH2) [44], or an intraventricular, subarachnoid, or parenchymal hemorrhage outside the infarct seen on neuroimaging, associated with a worsening of 4 or more points on the PedNIHSS or deterioration in the level of consciousness.

The NINDS and rt-PA Stroke Study group established the safety and efficacy of 0.9 mg/kg of intravenous tPA within 3 h of stroke onset [9]. Symptomatic intracranial hemorrhage occurred in 6.4% of treated adults compared with 0.6% of controls (p < 0.001) [45]. In the pilot studies there were no cases of symptomatic intracranial hemorrhage at intravenous tPA doses of 0.85 mg/kg given 0–90 min after stroke onset or 0.6 mg/kg at 91–180 min [46, 47]. Systemic thrombus in children has been reported to
respond to thrombolysis with lower doses of tPA than used in adults [48]. As it is unknown to what extent developmental hemostasis will impact thrombolysis and risk of hemorrhage, the TIPS trial will start with a conservative dose of intravenous tPA and increase in small increments: 0.6, 0.75, 0.9, and 1.0 mg/kg.

As thrombus is the target lesion for thrombolysis and arterial recanalization following stroke intervention predicts a more favorable outcome [49–51], immediate recanalization was initially considered as the surrogate response [52] for a Bayesian dose finding method for the intravenous arm. However, establishing the presence of immediate recanalization was not feasible in the intravenous arm. The role of transcranial Doppler in thrombolysis in stroke is not proven [53]. Although immediate recanalization may be seen on MRA, the risk of a prolonged study with the possible need for sedation was not felt to be justifiable in the immediate post-tPA period. A head CT angiogram would entail additional unacceptable radiation and contrast material exposure. Finally, adequate data regarding the comparability of these methods in assessing acute cerebral recanalization in childhood stroke is lacking. Recanalization status at 24 h is not an acceptable surrogate as re-occlusion [54] and late spontaneous recanalization can occur [55].

Dose escalations are planned in groups of 3, with an additional 3 patients to be added at the first indication of dose-limiting toxicity (DLT). An accrual rate of approximately 1 patient per 2 months is anticipated, with an estimated trial duration of 42 months, for a total of 24 patients, unless toxicity stops the trial earlier. The following dose escalation rules will be used. Three patients are studied at the first dose level. If none of these 3 patients experience DLT, then the dose is escalated to the next higher level in the 3 subsequent patients. If 1 of 3 patients experiences DLT at the current dose, then up to 3 more patients are accrued at the same level. If none of these 3 additional patients experience DLT, then the dose is escalated in subsequent patients. If 1 or more of these 3 additional patients experiences DLT, then patient entry at that dose level is stopped, the maximum tolerated dose has been exceeded and dose escalation will be stopped. Up to 3 more patients are treated at the next lower dose (unless 6 patients have already been treated at that prior dose). If 2 or more of a cohort of up to 6 patients experience DLT, then the maximum tolerated dose has been exceeded and dose escalation will be stopped. Up to 3 more patients are treated at the next lower dose (unless 6 patients have already been treated at that prior dose). Using this dose escalation scheme, the probability of escalating to the next dose level, based on the true rate of DLT at the current dose, is as follows: if true adverse effects at a given dose are 10, 20, 30, 40, 50, 60% then the probability of escalating to a higher dose is 0.91, 0.71, 0.49, 0.31, 0.17, 0.08, respectively.

Dose Determination and Dose Finding Method for the Intra-Arterial Arm

In the TIPS, there will be 4 dosing ranges for intra-arterial tPA, with the maximum reached at 60 kg weight: tier 1: maximum of 0.2 mg/kg (max. 12 mg); tier 2: maximum of 0.3 mg/kg (max. 18 mg); tier 3: maximum of 0.4 mg/kg (max. 24 mg, essentially equivalent to the IMS intra-arterial dose), and tier 4: maximum of 0.5 mg/kg (max. 30 mg). We hypothesize that within these ranges, the most desirable dose of intra-arterial tPA will be identified for treatment of AIS in children within 3–6 h of stroke onset. The Thall and Cook Bayesian method will be used to escalate or de-escalate the dose level for each patient [52] as they are enrolled in the study utilizing both toxicity and response data from patients treated previously in the trial as a basis to adaptively determine an acceptable dose among a predefined group of possible doses [52, 56, 57].

In adults, within 6 h of angiographically proven occlusion of the carotid circulation ‘low-dose’ tPA (10–20 mg) resulted in recanalization in 32% of patients, and ‘high-dose’ tPA (40–90 mg) resulted in recanalization in 50% [58]. In the IMS studies [41, 59], 0.6 mg/kg intravenous tPA for a maximum of 60 mg was given for acute large-vessel stroke. If on conventional angiogram persistent thrombus was seen, intra-arterial lysis with no more than a total of 22 mg of intra-arterial tPA could be administered. The total maximum dose of intravenous and intra-arterial tPA in the study was 82 mg as compared with a maximum dose of 90 mg in the NINDS tPA trial.

As thrombus is the target lesion for thrombolysis and arterial recanalization following stroke intervention predicts a more favorable outcome [49–51, 60], immediate recanalization will be used as the surrogate response. Recanalization is best assessed on conventional angiogram and late recanalization may be seen on MRA, the risk of a prolonged study with the possible need for sedation was not felt to be justifiable in the immediate post-tPA period. A head CT angiogram would entail additional unacceptable radiation and contrast material exposure. Finally, adequate data regarding the comparability of these methods in assessing acute cerebral recanalization in childhood stroke is lacking. Recanalization status at 24 h is not an acceptable surrogate as re-occlusion and late spontaneous recanalization can occur. [54] and late spontaneous recanalization can occur [55].

Dose escalations are planned in groups of 3, with an additional 3 patients to be added at the first indication of dose-limiting toxicity (DLT). An accrual rate of approximately 1 patient per 2 months is anticipated, with an estimated trial duration of 42 months, for a total of 24 patients, unless toxicity stops the trial earlier. The following dose escalation rules will be used. Three patients are studied at the first dose level. If none of these 3 patients experience DLT, then the dose is escalated to the next higher level in the 3 subsequent patients. If 1 of 3 patients experiences DLT at the current dose, then up to 3 more patients are accrued at the same level. If none of these 3 additional patients experience DLT, then the dose is escalated in subsequent patients. If 1 or more of these 3 additional patients experiences DLT, then patient entry at that dose level is stopped, the maximum tolerated dose has been exceeded and dose escalation will be stopped. Up to 3 more patients are treated at the next lower dose (unless 6 patients have already been treated at that prior dose). If 2 or more of a cohort of up to 6 patients experience DLT, then the maximum tolerated dose has been exceeded and dose escalation will be stopped. Up to 3 more patients are treated at the next lower dose (unless 6 patients have already been treated at that prior dose). Using this dose escalation scheme, the probability of escalating to the next
at the best acceptable dose determined by a toxicity-response trade-off function. If, at any point in the trial, it is determined that no dose is acceptable, then the trial will be terminated early with no dose selected.

This method has the advantage of allowing dose finding within a small sample size [52]. However, it requires that acceptable toxicity and response ratios be determined. For the TIPS trial, the maximum acceptable toxicity is 15%, based on incidence of symptomatic intracranial hemorrhage following intra-arterial lysis of 6–15% [35, 36, 62]. The dose finding formula will use the following points to define the curve of the minimum toxicity to efficacy ratio: accept 5% toxicity for 30% response, accept 10% toxicity for 45% response, and accept 15% toxicity for 60% response. The minimum acceptable response of 20% and the maximum acceptable toxicity is 15%, requiring 60–100% response.

Sample Size Estimates

A major challenge in TIPS is the limitation in sample size. Estimates were based on experience at institutions already enrolling patients within the IPSS and surveys of centers participating in the IPSS, reports to the IPSS database as well as feasibility studies, as above. The sample size limitation precludes a randomized, controlled study at this point. The statistical methods for the intravenous and intra-arterial methods were designed to optimize power within the sample size constraints.

Discussion

The TIPS study will establish the safety and feasibility of tPA in acute childhood AIS, and allow the design of a trial to determine the efficacy of tPA in acute childhood stroke. This will provide children who suffer acute stroke the same benefits of acute stroke intervention that have markedly improved stroke outcome in adults. The results of this work will be applicable worldwide to the pediatric population and are expected to improve the health and welfare of countless children.

Acknowledgments

The authors wish to thank Jeffrey Templeton for his helpful review of the manuscript and the collaborators from the International Pediatric Stroke Study for their support for this study. We thank Drs. Peter Thall, John Cook, and Harry Whelan for their assistance with statistical design, and Dr. Jane Madden for her expert review. Anthony Chan is a Career Investigator funded by the Heart and Stroke Foundation of Ontario. The International Pediatric Stroke Study is funded by the Canadian Stroke Network.

References


